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Introduction
Multivalvular disease has been documented in more 
than one-third of patients with a diagnosis of valvular 
heart disease.1) It has been reported that the prevalence of 
MS in patients with severe AS is around 10% and the 
outcome of these patients is very poor once they develop 
symptoms.2) The presence of combined AS and MS 
makes it difficult to evaluate the severity of each individ-
ual lesion because of hemodynamic interactions between 
the two lesions.
According to the 2014 American Heart Association/
American College of Cardiology guidelines, concomi-
tant mitral valve surgery is reasonable in patients with 
severe mitral stenosis (MS) (mitral valve area [MVA] 
≤1.5 cm2) who undergo other cardiac surgery.3) Gener-
ally, mitral valve replacement (MVR) is not performed 
for coexisting moderate MS (1.5 cm2 <MVA) in patients 
undergoing aortic valve replacement (AVR) for aortic 
stenosis (AS).
AS induces progressive myocardial fibrosis, 
reduced ventricular compliance, and diastolic dys-
function.4–9) AVR for AS leads to reverse myocardial 
remodeling,10) but the effect of AS treatment on coex-
isting MS is unclear. We evaluated postoperative clin-
ical outcomes in patients undergoing AVR for AS with 
moderate MS.
Purpose: The course of coexisting mitral valve stenosis is not clear after aortic valve 
replacement (AVR) for aortic stenosis (AS). We investigated the effect of AVR for AS on 
coexisting mitral stenosis (MS).
Methods: Between January 2002 and December 2019, 1338 consecutive patients under-
went surgical AVR at Shiga University of Medical Science. Of them, 34 patients with mod-
erate MS (mitral valve area [MVA]: 1.5–2.0 cm2) were included in the present study. We 
evaluated the postoperative clinical outcomes in these patients.
Results: Mean MVA in our cohort significantly increased 1 week after operation com-
pared with preoperative values, and the change was maintained for 5 years after surgery. 
Follow-up was completed in 94.1% (32/34) patients, and mean follow-up duration was 
4.0 ± 3.0 years. No patients underwent mitral surgery for remaining MS after AVR during 
postoperative follow-up.
Conclusion: AVR for AS resulted in increased MVA in patients with MS, and the change 
was maintained during follow-up.
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Materials and Methods
The study was approved by the review board of Shiga 
University of Medical Science (approval No. R2020-077) 
and all patients had previously provided informed consent 
for use of their medical records for research purposes. 
Between January 2002 and December 2019, 1338 consecu-
tive patients underwent surgical AVR at Shiga University of 
Medical Science. Of them, 34 patients with moderate MS 
(MVA: 1.5–2.0 cm2) were included in the present study.
Surgical treatment
Patients were placed in the supine position, and anes-
thesia was maintained in the standard manner. Valve 
choice was based on each surgeon’s preference. Bio-
prosthetic valves were implanted in the supra-annular 
position and mechanical valves were implanted in the 
intra-annular position. Myocardial protection was 
obtained for all patients with antegrade or retrograde 
infusion using cold blood cardioplegia solution.
Echocardiographic measurements
Patients underwent annual echocardiographic follow-up 
at our institution. MVA was estimated in the apical 
four-chamber view using spectral continuous color Dop-
pler traces of diastolic transmitral flow. The pressure half 
time (PHT), the time interval between the maximum 
early diastolic pressure gradient, and the point where the 
gradient is half the maximum value were obtained. MVA 
was calculated as 220 divided by PHT. Aortic valve area 
(AVA) was calculated by reconfiguration of the continuity 
equation. The dimensions of the left ventricle were assessed 
using two-dimensionally guided M-mode tracing.
Mitral annulus calcification (MAC) was defined as the 
presence of dense calcium deposits at the base of the 
mitral leaflets between the left atrium and ventricle.11,12) 
The extension of calcification to both anterior and poste-
rior mitral leaflets was evaluated from parasternal long 
axis view.13) Rheumatic MS was defined when typical fea-
tures such as leaflet thickening, nodularity, commissural 
fusion, and chordal fusion and shortening were present.
Statistical analysis and data collection
Continuous variables are presented as mean ± stan-
dard deviation or median and interquartile range. 
Categorical variables are presented as percentages. 
Comparisons of patients’ clinical outcomes between the 
two groups were performed using unpaired t-tests for 
normally-distributed variables or the Mann–Whitney U 
test for skewed variables. Univariable and multivariable 
logistic regression analyses were performed to identify 
the independent predictors of postoperative MS. Vari-
ables reaching p <0.050 in the univariable analysis or 
that were considered clinically important were entered 
into the multivariable model. The Kaplan–Meier method 
was used to describe survival rates. All statistical testing 
was two-sided. Results were considered statistically sig-
nificant at p <0.050, and all statistical analyses were per-
formed using the Statistical Package for Social Sciences, 
version 25.0 (IBM Corp., Armonk, NY, USA) and SAS, 
version 9.4 (SAS Institute Inc., Cary, NC, USA).
Results
Preoperative characteristics are listed in Table 1. The 
mean age of our study population was 77.9 ± 8.3 years, 
and seven patients were male (20.6%). In all, 30 patients 
(88.2%) had MAC and three patients (8.8%) had exten-
sion of calcification to both anterior and posterior mitral 
leaflets. In all, 13 patients had mild regurgitation preoper-
atively and the other 21 patients had less than mild. Oper-
ative and postoperative data are shown in Table 2. Seven 
patients (20.6%) underwent concomitant coronary artery 
bypass grafting and two patients (5.9%) underwent con-
comitant thoracic aortic surgery. No patients underwent 
Table 1 Preoperative patient characteristics
Number of patients 34
Age (year) 77.9 ± 8.3
Sex (male) 7 (20.6%)
Body mass index (kg/m2) 21.9 ± 4.0
Hypertension 22 (64.7%)
Diabetes mellitus 8 (23.5%)
Dyslipidemia 9 (26.5%)
Smoking history 7 (20.6%)
Previous cerebral vascular disease 5 (14.7%)
Previous percutaneous coronary  
intervention
5 (14.7%)
Peripheral artery disease 4 (11.8%)
Serum creatinine (mg/dL) 1.23 (0.89 - 2.92)
Dialysis 9 (26.5%)
HbA1c (%) 5.6 ± 0.9
Bicuspid aortic valve 1 (2.9%)
Rheumatic 3 (8.8%)
Mitral annulus calcification 30 (88.2%)
Extension of calcification to leaflets 3 (8.8%)
Mitral regurgitation
 Mild 13 (38.2%)
 Trivial 20 (58.8%)
 None 1 (2.9%)
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concomitant tricuspid valve surgery or mechanical AVR 
in our cohort. Additionally, no patients underwent de-cal-
cification procedure of mitral valve anterior leaflet. One 
patient died of sepsis 15 days after surgery.
Table 3 shows the hemodynamic changes before and 
after AVR. The preoperative mean value of MVA was 
1.80 ± 0.15 cm2 (1.51–2.00 cm2) and the preoperative 
mean AVA was 0.79 ± 0.19 cm2. MVA (p < 0.001), left 
ventricular end diastolic diameter (p = 0.033), AVA (p 
<0.001), indexed AVA (p <0.001), aortic valve peak 
velocity (p <0.001), aortic valve peak pressure gradient 
(p <0.001), and aortic valve mean pressure gradient (p 
<0.001) were significantly changed 1 week postopera-
tively compared with values before AVR, and the changes 
were maintained for 5 years after the operation. Figure 1 
shows the changes in MVA over time. In all patients, 
MVA increased 1 week postoperatively compared with 
preoperatively (p <0.001). Left ventricular end systolic 
diameter significantly decreased 3 months postopera-
tively (p = 0.001), and the changes were maintained for 
4 years after surgery. Left ventricular mass significantly 
regressed 3 months postoperatively (p = 0.001), and the 
changes were maintained for 5 years after the operation.
Follow-up was completed in 94.1% (32/34) of the 
patients, and the mean follow-up duration was 4.0 ± 3.0 
years (maximum: 11.6 years). One patient died of stroke, 
one patient died of caducity, and one patient died of 
unknown causes. The 5-year estimated rate of survival 
free from overall death was 91.4% (Fig. 2). In one patient 
in our cohort, MVA decreased to less than 1.5 cm2 during 
the postoperative follow-up. Multivariable logistic 
regression analysis revealed that there was no indepen-
dent predictor of postoperative MS (MVA <1.5 cm2). 
No patient underwent mitral surgery for remaining MS 
after AVR during postoperative follow-up.
Discussion
As the prevalence of rheumatic fever decreases glob-
ally, the incidence of rheumatic MS is decreasing. In 
contrast, there is an increase in the incidence of MAC 
with degenerative MS because of an increasing aging 
patient population with multiple comorbidities such as 
chronic kidney disease and diabetes mellitus.14) In the 
presence of MAC, it is difficult to evaluate diastolic 
function using Doppler tissue imaging such as E-wave, 
E/e’ ratio, and deceleration time. Although left atrial 
diameter is also considered as an indicator of diastolic 
function, it is not feasible for evaluation of diastolic 
function when MS remains after AVR for AS. Therefore, 
the improvement of diastolic function after AVR for AS 
in patients with MS is difficult to measure.
One of the major findings of the current study is that 
an increase in MVA after AVR was observed 1 week 
after surgery. To the best of our knowledge, this is the 
first study assessing the speed of change of MVA after 
AVR for AS. Previous studies have regarded MS as a 
potential risk factor for increased cardiac morbidity and 
mortality,15,16) so the rapid increase in MVA in patients 
undergoing AVR is meaningful. Diastolic PHT is depen-
dent not only on the degree of mitral obstruction but also 
the compliance of the left ventricle and left atrium.1) 
Ikonomidis et al. have reported improvement of diastolic 
function 2 weeks after surgery in patients undergoing 
AVR for AS.17) Sari et al. have reported the recovery of 
left atrial and left ventricular diastolic function 24 hours 
after transcatheter aortic valve implantation.18) In our 
study, acute improvement of left atrial and left ventricu-
lar diastolic function after AVR may have resulted in the 
improvement of MVA 1 week after surgery. Addition-
ally, MVA increased 1 week postoperatively compared 
with preoperative values in all patients. Brown et al. have 
reported that patient–prosthesis mismatch after AVR is 
associated with persisting diastolic dysfunction.19) No 
patients had 1-week postoperative indexed AVA ≤0.85 
cm2/m2 in our cohort, which may have resulted in the 
increased MVA observed in all patients.
Another finding of our study is that the increase in 
MVA after AVR was maintained for 5 years after sur-
gery. Improvement in diastolic function after AVR has 
mainly been attributed to the subsequent regression of 
left ventricular hypertrophy.20) In the present study, left 
ventricular mass slowly regressed over 5 years postoper-
atively (Table 3). Therefore, the improved diastolic 
function after AVR was maintained by the persistent 
Table 2 Operative and postoperative data
Operative data
 Operation time (m) 215 ± 45
 Cardiopulmonary bypass time (m) 102 ± 30
 Surgical details
   Concomitant coronary artery bypass 
grafting
7 (20.6%)
  Concomitant tricuspid valve surgery 0 (0%)
  Concomitant thoracic aortic surgery 2 (5.9%)
Postoperative data
 Myocardial infarction 0 (0%)
 Stroke 3 (8.8%)
 Intensive care unit stay > 48 hour 3 (8.8%)
 Ventilation > 48 hour 2 (5.9%)
 30-day mortality 1 (2.9%)



























Number of followers 34 32 28 22 16 15 14 12
Mitral valve area (cm2) 1.80 ± 0.15 2.41 ± 0.40 <0.001 2.42 ± 0.46 <0.001 2.32 ± 0.41 <0.001 2.26 ± 0.58 0.007 2.27 ± 0.57 0.006 2.19 ± 0.62 0.033 2.32 ± 0.48 0.006
Left ventricular 
ejection fraction (%)
61.1 ± 8.5 59.5 ± 7.9 0.443 62.5 ± 5.6 0.448 63.0 ± 4.6 0.265 64.0 ± 3.4 0.079 61.5 ± 2.1 0.423 62.3 ± 4.4 0.406 62.2. ± 3.7 0.710
Left ventricular end 
diastolic  
diameter (mm)
48.6 ± 7.3 45.0 ± 6.2 0.033 42.4 ± 4.7 <0.001 42.3 ± 3.1 <0.001 42.2 ± 3.8 <0.001 44.4 ± 5.2 0.014 41.9 ± 3.8 0.004 42.5 ± 3.8 0.027
Left ventricular end 
systolic  
diameter (mm)
32.5 ± 7.0 31.2 ± 5.2 0.412 27.8 ± 3.2 0.002 27.9 ± 2.8 0.001 27.7 ± 3.2 0.001 29.3 ± 3.7 0.043 26.7 ± 2.9 <0.001 28.3 ± 2.9 0.109
Left ventricular 
mass (g)
253 ± 87 225 ± 72 0.155 187 ± 52 0.001 175 ± 47 0.001 162 ± 41 <0.001 169 ± 37 <0.001 163 ± 34 0.001 161 ± 47 0.001
Left atrial  
diameter (mm)
45.3 ± 7.6 42.9 ± 6.9 0.184 42.7 ± 6.9 0.162 41.3 ± 6.0 0.038 42.8 ± 4.7 0.204 45.4 ± 6.1 0.702 43.1 ± 6.4 0.368 41.8 ± 6.0 0.235
E/e' (lateral) 19.3 ± 10.4 22.5 ± 12.0 0.308 20.0 ± 9.9 0.804 19.9 ± 10.6 0.837 19.2 ± 7.3 0.983 25.2 ± 12.9 0.126 24.3 ± 8.3 0.226 28.7 ± 9.9 0.040
E/e' (septal) 25.7 ± 14.3 28.0 ± 11.9 0.529 29.2 ± 14.5 0.399 28.0 ± 14.5 0.572 29.6 ± 9.2 0.321 30.7 ± 10.4 0.264 29.0 ± 9.6 0.573 34.0 ± 9.3 0.158
Aortic valve
Aortic valve area (cm2) 0.79 ± 0.19 1.72 ± 0.31 <0.001 1.72 ± 0.26 <0.001 1.80 ± 0.25 <0.001 1.71 ± 0.26 <0.001 1.71 ± 0.27 <0.001 1.71 ± 0.31 <0.001 1.67 ± 0.23 <0.001
Indexed aortic valve 
area (cm2/m2)
0.56 ± 0.13 1.23 ± 0.23 <0.001 1.23 ± 0.23 <0.001 1.30 ± 0.21 <0.001 1.21 ± 0.19 <0.001 1.21 ± 0.20 <0.001 1.20 ± 0.23 <0.001 1.18 ± 0.17 <0.001
Peak velocity (m/s) 4.8 ± 0.8 2.5 ± 0.6 <0.001 2.4 ± 0.4 <0.001 2.2 ± 0.4 <0.001 2.3 ± 0.5 <0.001 2.1 ± 0.4 <0.001 2.3 ± 0.7 <0.001 2.6 ± 0.9 <0.001
Peak pressure  
gradient (mmHg)
92.8 ± 30.6 26.1 ± 13.2 <0.001 23.4 ± 8.5 <0.001 21.6 ± 7.3 <0.001 22.4 ± 9.6 <0.001 18.9 ± 7.4 <0.001 22.1 ± 13.1 <0.001 28.9 ± 19.6 <0.001
Mean pressure 
gradient (mmHg)
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regression of left ventricular mass, which may have 
resulted in a sustained increase of MVA.
For MS with a high frequency of MAC, performing 
MVR carries the risks of causing complications such as 
atrioventricular disruption, left ventricular rupture, and 
neurological complications due to calcium embolization. 
Moreover, performing AVR for AS in addition to MVR 
further increases the risk of surgery. However, perform-
ing mitral valve surgery for MS as a reoperation after 
AVR surgery is a high-risk procedure. In the present 
study, increased MVA was maintained for 5 years after 
surgery, and no patients underwent reoperation for 
remaining MS. This result may be useful for understand-
ing the pathophysiology of combined valvular disease of 
AS and MS.
Multivariable logistic regression analysis showed that 
there was no independent predictor of postoperative MS 
(MVA <1.5 cm2). However, MVA only decreased to less 
than 1.5 cm2 in one patient during our follow-up. This 
result may be due to the small number of samples. A 
much larger study is needed to accurately evaluate the 
postoperative course of remaining MS after AVR for AS.
Study Limitations
There are several limitations in this study. First, this is 
a retrospective study in a single center. Second, the small 
number of patients might have resulted in insufficient 
statistical power. Third, the main evaluation method for 
the severity of MS is the evaluation of MVA using PHT 
and planimetry orifice area was used as a supplement in 
our institution. Of all echocardiographic reports in our 
all cohort, only 84 (48.6%) reports revealed planimetry 
orifice area, so we could not show the MVA using 
planimetry orifice area. Other measurements such as 
planimetry orifice area and transmitral gradient should 
be measured preoperatively and postoperatively. Finally, 
the follow-up period was short at 4.0 ± 3.0 years after 
operation, which could explain why no patients under-
went reoperation for remaining MS.
Conclusions
AVR for AS resulted in increased MVA in patients with 
MS, and the change remained for during follow-up. This 
result may be meaningful for understanding the patho-
physiology of combined valvular disease of AS and MS.
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